Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | CHIT1 | Q13231 | 2/20 | 0.39 |
| ▸ | CHIA | Q9BZP6 | 2/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7950557 | 0.86 | TDP1 (0.41) | TDP1L3MBTL1MITFSLC6A2SLC6A4 | |
| SCHEMBL5695790 | 0.85 | TDP1 (0.45) | TDP1L3MBTL1MITFCA1CA2 | |
| SCHEMBL5695792 | 0.85 | TDP1 (0.47) | TDP1L3MBTL1MITFESR1SLC6A2 | |
| SCHEMBL2115137 | 0.85 | MITF (0.57) | TDP1L3MBTL1MITFCA1CA2 | |
| SCHEMBL27629296 | 0.83 | TDP1 (0.51) | TDP1L3MBTL1MITFCA1CA2 | |
| SCHEMBL3738377 | 0.82 | TDP1 (0.41) | TDP1L3MBTL1MITFCHIT1CHIA | |
| SCHEMBL6711052 | 0.81 | TDP1 (0.39) | TDP1L3MBTL1MITFCHIT1CHIA | |
| SCHEMBL28861068 | 0.78 | SLC6A2 (0.47) | TDP1L3MBTL1MITFSLC6A2SLC6A4 | |
| SCHEMBL9812322 | 0.78 | TDP1 (0.41) | TDP1L3MBTL1MITFSLC6A2SLC6A4 | |
| SCHEMBL7771962 | 0.77 | CA1 (0.39) | TDP1L3MBTL1MITFCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2388003-B1 | Colchicine derivatives | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3207929-B1 | COLCHICINE DERIVATIVES FOR THE TREATMENT OF CANCER | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3207929-A2 | COLCHICINE DERIVATIVES | California Pacific Medical Center (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-1617843-B1 | COLCHICINE DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-1643987-B1 | PODOPHYLLOTOXIN DERIVATIVES | CALIFORNIA PACIFIC MED CENTER (US) | 2016-11-30 | — | — | EP | disclosed |
| US-8158809-B2 | Podophyllotoxin derivatives | SUTTER WEST BAY HOSPITALS (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2388003-A2 | Colchicine derivatives | California Pacific Medical Center (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20090298870-A1 | PODOPHYLLOTOXIN DERIVATIVES | Sutter West Bay Hospitals, dba California Pacific Medical Center and Catholic Healthcare West | 2009-12-03 | — | — | US | disclosed |
| US-7605262-B2 | Podophyllotoxin derivatives | SUTTER WEST BAY HOSPITALS (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080113941-A1 | Podophyllotoxin Derivatives | CALIFORNIA PACIFIC MEDICAL CENTER | 2008-05-15 | — | — | US | disclosed |
| US-6825236-B2 | ACTIVE AGAINST TUMORS IN MICE AND ARE GENERALLY WELL TOLERATED | CALIFORNIA PACIFIC MEDICAL CENTER | 2004-11-30 | — | — | US | disclosed |
| US-6825207-B2 | ANTICANCER AGENTS | CALIFORNIA PACIFIC MEDICAL CENTER | 2004-11-30 | — | — | US | disclosed |
| US-20040204370-A1 | COLCHICINE DERIVATIVES | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2004-10-14 | — | — | US | disclosed |
| US-20040063740-A1 | For treatment of cancer | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2004-04-01 | — | — | US | disclosed |
| EP-1383772-A2 | NITROGEN-BASED CAMPTOTHECIN DERIVATIVES | California Pacific Medical Center (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003101998-A1 | NITROGEN-BASED HOMO-CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2003-12-11 | — | — | WO | disclosed |
| US-20030073698-A1 | Nitrogen-based camptothecin derivatives | US ARMY, SECRETARY OF THE ARMY | 2003-04-17 | — | — | US | disclosed |
| US-20030032624-A1 | Nitrogen-based camptothecin derivatives | US ARMY, SECRETARY OF THE ARMY | 2003-02-13 | — | — | US | disclosed |
| WO-2002070525-A2 | NITROGEN-BASED CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2002-09-12 | — | — | WO | disclosed |
| US-6403604-B1 | ANTITUMOR | CALIFORNIA PACIFIC MEDICAL CENTER | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063740-A1 | For treatment of cancer | MGMT, PAICS, DCK | TDP1 2375/4885L3MBTL1 3543/4885LTA4H 627/4885 |
| US-20080113941-A1 | Podophyllotoxin Derivatives | APEH, DAGLA, DPY30 | TDP1 1322/4885L3MBTL1 274/4885LTA4H 103/4885 |
| US-20030073698-A1 | Nitrogen-based camptothecin derivatives | DCK, NEK11, NME1 | TDP1 1142/4885L3MBTL1 3149/4885LTA4H 2297/4885 |
| US-20040204370-A1 | COLCHICINE DERIVATIVES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, NAP1L4 | TDP1 1571/4885L3MBTL1 1518/4885LTA4H 3722/4885 |
| US-20090298870-A1 | PODOPHYLLOTOXIN DERIVATIVES | APEH, DAGLA, DPY30 | TDP1 1322/4885L3MBTL1 274/4885LTA4H 103/4885 |
| US-20030032624-A1 | Nitrogen-based camptothecin derivatives | DCK, NEK11, NME1 | TDP1 1142/4885L3MBTL1 3149/4885LTA4H 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.